Radiopharm Theranostics Limited American Depositary Shares RADX · USD
Health Care · US listing · 🇺🇸 United States
0.89
-7.70%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Radiopharm Theranostics Limited American Depositary Shares
Its shares trade under the ticker RADX. It has been listed since 5 December 2024. In the fiscal year to 30 June 2026, it reported revenue of $2.7m and a net loss of $53.9m. At that date it held total assets of $60.1m and shareholders' equity of $24.7m.
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 5 Dec 2024
- Employees
- 14
- Website
- radiopharmtheranostics.com ↗
- Head office
- LEVEL 3, 62 LYGON STREET, CARLTON VIC, 3053
- Incorporated in
- C3
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Emerging growth company
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Radiopharm Theranostics Limited develops multiple radiopharmaceutical products for high unmet medical needs in diagnostic and therapeutic areas.
- The company has strategic agreements with Lantheus Holdings, Inc. to advance clinical development of radiopharmaceuticals.
- Radiopharm Theranostics Limited has a clinical-stage focus with 14 employees and a 2021 incorporation date.
Weaknesses
- The company has only 14 employees, which may limit its operational capacity and scalability.
- Radiopharm Theranostics Limited is based in Carlton, Australia, a location with limited access to major healthcare markets.
- The company's products are still in clinical stages, requiring significant future investment for market entry.
Opportunities
- The company's strategic agreement with Lantheus Holdings, Inc. offers potential for expanded clinical development and market access.
- Radiopharm Theranostics Limited's focus on high unmet medical needs in areas like brain metastasis and HER-2 breast cancer presents significant market opportunities.
- The company's product pipeline includes multiple diagnostic and therapeutic options for various cancers, including prostate and glioblastoma.
Threats
- Radiopharm Theranostics Limited faces competition from established players in the Health Care sector with larger resources.
- The clinical development of radiopharmaceuticals requires substantial capital investment, posing financial risks.
- The company's reliance on a single strategic agreement with Lantheus Holdings, Inc. could create dependency risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.